Abstract
Estrogen receptor (ER) expression in breast carcinomas, determined by immunohistochemistry, indicates statistically significant benefit to endocrine therapy in patients with tumors expressing ER in ≥1% of tumor cells. Rare cases with low ER expression (1–10%) lead to the dilemma of treating these tumors as ER positive or negative. We hypothesize that low ER positive result from poor staining performance and that we may detect this artefact by assessing the average dynamic range of normal ducts adjacent to low ER positive tumors. Using quantitative tools, we compare the dynamic range of normal background ER expression in patients with low (1–10%) ER tumors to dynamic range of ER expression in normal epithelium from control patient populations, to determine if low ER cases are accompanied by decreased dynamic range. Low ER cases were infrequent (1% of invasive breast carcinomas). Twenty-one cases with low ER staining and two control cohorts, including a tissue microarray (TMA) of 10 benign breast sections and a group of 34 control breast carcinomas (reported as ER negative or >10% ER positive) with normal background epithelium, were digitally scanned. QuPath was utilized to quantify ER staining for each cell as the mean optical density of nuclear DAB staining. The dynamic range of ER expression in normal epithelium surrounding low ER tumors was significantly lower (range 2–240, median 16.5) than that of the benign epithelium in the control tumors (range 3–475, median 30.8; p < 0.001) and benign TMA sections (range 38–212, median 114; p < 0.001) suggesting inconsistent stainer performance.
Highlights
Estrogen receptor (ER) is expressed in the majority of invasive breast carcinomas and is an important predictive and prognostic marker
Low ER carcinoma clinical cases The pathology database search identified that ER IHC was performed on 3786 cases of invasive breast carcinomas following the updated 2010 ASCO/CAP guidelines, 40 (1.05%) of which were reported as demonstrating low (1–10%) ER expression
The hormone receptor and human epidermal growth factor receptor 2 (HER2) status of breast carcinomas is the foundation on which treating physicians determine appropriate clinical management for patients
Summary
Estrogen receptor (ER) is expressed in the majority of invasive breast carcinomas and is an important predictive and prognostic marker. The standard of care is to report the percentage of cells positive “at any intensity” but there is no routine method for standardization for intensity. We depend on standardized, often closed system staining protocols to define the intensity threshold. While this method appears to have been effective in standardization, if the threshold moves up or down, the percentage of positive cells could vary, but in a manner that goes undetected. Years ago, this approach led to some significant under-calling of ER positive cases in some provinces in Canada.[7,8]
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have